Fertility Testing Market Size was valued at USD 0.59 Billion in 2023. The Global Fertility Testing industry is projected to grow from USD 0.65 Billion in 2024 to USD 1.25 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.63% during the forecast period (2024 - 2032). Fertility testing is a medical and physical assessment that tests the ability to become pregnant naturally. One of the things that could affect fertility is getting older; therefore, if, after six months of trying, men and women over 35 are still having problems getting pregnant, they might consider fertility testing.Â
The fertility testing process includes blood tests, discussions of medical history, and minimally invasive procedures. It mostly involves looking for hormones like luteinizing or progesterone in blood, urine, or saliva to ascertain whether ovulation has occurred. Semen analysis is a component of male testing to guarantee a healthy sperm count. The fertility testing market expansion is related to an increase in conditions like Polycystic Ovary Syndrome (PCOS), which causes women to ovulate irregularly every month due to the ovaries' excessive estrogen synthesis.
COVID-19 Impact Analysis
As per the target market report, a significant source of difficulty for the reproductive testing industry has been the COVID-19 pandemic. Due to the outbreak's high contagiousness, numerous in-person reproductive treatment procedures have been paused. It has interfered with the industry's efficient operation in many different places. The demand for fertility testing has been impacted ly by the tight social distancing guidelines and restrictions. Due to the pandemic, many couples now find it challenging to acquire fertility testing services. However, companies in the market have been developing cutting-edge strategies so fertility testing facilities can continue operating while observing legal requirements. While gender roles and social norms lessened the impact of the pandemic, the health crisis, economic downturn, and social isolation caused an alteration in fertility behavior.
January 2024
Zora Health, a company located in Singapore, has made an announcement on the debut of their comprehensive fertility treatment and finance platform, which is supported by investment of $740,000. The following noteworthy angel investors took part in this investment round: Cheryl Goh, who was the founding chief marketing officer of Grab; Prajit Nanu, who is the chief executive officer of Nium; Alan Jiang, who is the chief executive officer of Beam; Lisa Enckell, who is a venture partner at Antler; and Asa Liden, who was the former chief operating officer of Pitch.com. In the beginning, the startup received backing from the venture capital firm Antler.
The environment of fertility therapy is intimidating for women and couples who are looking for reproductive care since there are a number of service alternatives and providers, numerous laws, and confusing price structures. Zora Health's comprehensive strategy tackles these problems head-on, making the process easier for patients, healthcare providers, and enterprises operating in a fragmented market, according to Anna Haotanto, the founder and chief executive officer of Zora Health.
A whole ecosystem is provided by the organization, which includes both online and in-person consultations, medical concierge services, reproductive education courses, and funding options for fertility treatment. Egg freezing, in vitro fertilization (IVF), fertility testing, and consulting services are some of the first services included into the company's offerings. In addition, Zora Health caters to corporate customers by establishing programs that aim to create work cultures that are fertility-friendly and to increase conversations about fertility. The platform underscores the fact that resolving reproductive difficulties may considerably improve both the emotional well-being of employees and their ability to remain with the company.
The firm claims that Zora Health already has a waitlist that includes more than 180 patients and that it has connections with more than 50 clinics located in sixteen locations across eight different nations. The newly acquired cash will be used to make the Zora Health platform available for use and to further develop it.
As per the market dynamics, due to the rising average age of first pregnancies, dropping fertility rates ly, and the release of advanced, user-friendly fertility monitors with high accuracy, favorable market growth circumstances are anticipated throughout the projection period. The rise of the industry is also expected to be fueled by other reasons, such as changing lifestyles and growing public knowledge of fertility testing. But over the projected period, the less accurate ovulation prediction kits and the unproven accuracy of urine-based ovulation monitors in PCOS/PCOD patients might limit the market growth. Therefore, these factors are projected to increase the  market size during the forecast period.Â
Market Drivers
The market report suggests that the average age of first-time pregnancy has increased dramatically across the globe due to the drop in first births among teenage women and the increase in first births among women over 30 years. According to the OECD, women currently give birth at an average age of 30 or more; women around the globe are increasingly choosing to delay their first pregnancies, which is why this change is being observed. Thus, the rising rate of first-time pregnancy drives the market growth. Thus it acts as a market driver.
Maeket Restraints:
Ovulation prediction kits measure the luteinizing hormone (LH) increase that occurs 24-36 hours before ovulation. However, these kits can't be used to confirm ovulation properly. In situations like luteinized unruptured follicle syndrome, ovulation predictors are unreliable, which occurs when a woman's egg does not separate from her follicle after the LH surge. Additionally, a measurement of urine LH only forecasts the start of ovulation. It cannot establish the date of ovulation or anovulation, indicating a very brief viable window (of only about two days). Ovulation monitors can detect only LH; they cannot identify other essential ovulation markers, such as if the cervical mucus is fertile-friendly. Thus, per market research, the lesser precision of ovulation prediction kits may limit the market.
Market Opportunities:
According to the market overview, players in the fertility test market can expect considerable growth possibilities in emerging economies like China, India, Brazil, and Mexico. Due to rising infertility rates, an increase in the prevalence of PCOS and obesity, an increase in fertility education, and the accessibility of fertility monitors through e-commerce websites, pharmacies, and retail shops/drugstores, the demand for fertility and ovulation monitors in emerging countries is anticipated to increase significantly in the coming years. Additionally, corporations have been incentivized to concentrate on emerging markets because of the friendlier regulatory frameworks and lower levels of player competition in developing markets than in developed ones.
The fertility testing market segmentation, based on product, is ovulation testing kits, fertility monitors, and others. The fertility testing market growth was high under the ovulation testing kits segment in 2021 due to the increased use of ovulation testing kits and the easy availability of over-the-counter test kits for at-home testing.
The fertility testing market segmentation, based on gender, is male and female. The female fertility testing segment had a prominent share in 2021 due to the availability of a wide range of fertility testing products for females, technologically advanced testing kits which predict accurate ovulation dates, and decreasing female fertility rates.
Based on the distribution channel, the  market is divided into hospital pharmacy, retail pharmacy, and online pharmacy. The retail pharmacy segment had a prominent share in 2021. The growing number of pharmacies and chains, with the availability of medications in supermarkets and mass retailers in countries like the UK and US, is driving the retail pharmacy segment.
Based on region, the  fertility testing market has been divided into North America, Europe, Asia-Pacific, and the Rest of the World. North America accounted for the most extensive market share. Asia-Pacific is projected to exhibit the highest CAGR during the forecast period.
Asia-Pacific
Asia-Pacific experienced the fastest growth in infertility testing in 2021. The market for pregnancy and ovulation tests in Asia-Pacific is expanding due to the increased demand for rapid, self-contained tests and the rising average age of first pregnancies. The market research in this area also suggests its expansion due to higher birth rates and a large rise in young people living there.
North America
North America dominated the  fertility test market in 2021 due to rising awareness of pregnancy detection techniques and fertility rates. A favorable environment for market expansion exists in the Americas due to the increased prevalence of adolescent pregnancy and the existence of significant market participants.
 Fertility Testing Market Competitive Landscape
The market is moderately competitive, and local and foreign businesses can be found there. Several businesses concentrate on introducing new products to maintain competitiveness, and it has been noted that few new businesses are joining the market under study, escalating competition. In January 2022, leading reproductive and family-building care provider, Kindbody introduced its consumer products business, Kind at Home. Easy-to-use at-home fertility hormone tests for both men and women will be the first offering from Kind at Home. Furthermore, in March 2022, Ro announced the acquisition of Dadi, a male fertility and sperm-testing firm, to expand its fertility services.
Prominent players in the  fertility testing market research includeÂ
Objectives of the Study
The objectives of the study are summarized in 5 stages. They are as mentioned below:
To identify and estimate the market size for the  fertility testing market report segmented by product, gender & distribution channel by value (in U.S. dollars). Also, to understand the consumption/ demand created by consumers of fertility testing market forecast between 2022 and 2030
To identify and infer the drivers, restraints, opportunities, and challenges in the  fertility testing market growth
To find out the factors which are affecting the fertility testing market size among consumers
To identify and understand the various factors involved in the  market affected by the pandemic
To provide a detailed insight into the major companies operating in the market. The profiling will include the financial health of the company's past 2-3 years with segmental and regional revenue breakup, product offering, recent developments, SWOT analysis, and key strategies.
Intended Audience
| Attribute/Metric | Details |
| Market Size 2023 | 0.59 (USD Billion) |
| Market Size 2024 | 0.65 (USD Billion) |
| Market Size 2032 | 1.25 (USD Billion) |
| Compound Annual Growth Rate (CAGR) | 7.63 % (2024 - 2032) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Base Year | 2023 |
| Market Forecast Period | 2024 - 2032 |
| Historical Data | 2019 - 2023 |
| Geographies Covered | North America, Europe, Asia-Pacific, and the Rest of the World (RoW) |
| Key Vendors | Fertility Focus Limited, Geratherm Medical AG, UEBE Medical GmbH, Church & Dwight Co., Inc., Ava AG, Fairhaven Health, Lady Technologies, SPD Swiss Precision Diagnostics GmbH, Samplytics Technologies Private Limited., The Boots Company PLC (Walgreens Boots Alliance), SNOWDEN, AdvaCare Pharma USA, and HiLin Life Products Inc. |
| Key Market Opportunities | Emerging nations to offer new growth avenues |
| Key Market Drivers | Increasing first-time pregnancy age |
Fertility Testing Market Highlights:
Frequently Asked Questions (FAQ) :
The study period of the fertility testing market is 2024 - 2032
The fertility testing market is growing at a CAGR of 7.63% over the next 10 years.
Asia-Pacific is expected to register the highest CAGR during 2024 - 2032
North America held the largest share in 2023
Fertility Focus Limited, Geratherm Medical AG, UEBE Medical GmbH, Church & Dwight Co., Inc., Ava AG, Fairhaven Health, Lady Technologies, SPD Swiss Precision Diagnostics GmbH, Samplytics Technologies Private Limited., The major companies operating in the fertility testing market are the Boots Company PLC (Walgreens Boots Alliance), SNOWDEN, AdvaCare Pharma USA, and HiLin Life Products Inc.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
